Lortalamine

In this article, the topic of Lortalamine will be addressed from various angles and perspectives in order to offer the reader a complete and detailed vision of it. Different aspects related to Lortalamine will be explored, its implications in different contexts will be analyzed and varied opinions and points of view will be presented. From its emergence to its impact on current society, this article aims to deepen the understanding of Lortalamine and offer the reader a broad and objective overview of this topic.

Lortalamine
Clinical data
Routes of
administration		Oral
ATC code
  • None
Pharmacokinetic data
Elimination half-life5 hours
ExcretionRenal (98%)
Identifiers
  • 8-chloro-1,2,3,4,10,10a-hexahydro-2-methyl-4a,10-(iminoethano)-4aH--benzopyrano-pyridin-12-one
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC15H17ClN2O2
Molar mass292.76 g·mol−1
3D model (JSmol)
  • Clc1ccc2O34NC(=O)C(c2c1)4CN(C)CC3

Lortalamine (LM-1404) is an antidepressant which was synthesized in the early 1980s.[1][2] It acts as a potent and highly selective norepinephrine reuptake inhibitor.[3][4] Lortalamine was under development for clinical use but was shelved, likely due to the finding that it produced ocular toxicity in animals.[5][6] It has been used to label the norepinephrine transporter in positron emission tomography studies.[4][7][8]

See also

References

  1. ^ David J. Triggle (1997). Dictionary of pharmacological agents. London: Chapman & Hall. ISBN 0-412-46630-9.
  2. ^ Belleville M, Grand M, Briet P (1981). "Plasma levels, elimination and metabolic fate of 4a-amino-8-chloro-2-methyl-1,2,3,4,4a,10a-hexahydro-10H-benzopyrano[3,2-c]pyridin-10-ylacetic acid lactam, a new antidepressive agent, in rats and dogs". Drug Metabolism and Disposition. 9 (3): 233–9. PMID 6113932.
  3. ^ Depin JC, Betbeder-Matibet A, Bonhomme Y, Muller AJ, Berthelon JJ (1985). "Pharmacology of lortalamine, a new potent non-tricyclic antidepressant". Arzneimittel-Forschung. 35 (11): 1655–62. PMID 4091869.
  4. ^ a b Lin KS, Ding YS (August 2005). "Synthesis and C-11 labeling of three potent norepinephrine transporter selective ligands ((R)-nisoxetine, lortalamine, and oxaprotiline) for comparative PET studies in baboons". Bioorganic & Medicinal Chemistry. 13 (15): 4658–66. doi:10.1016/j.bmc.2005.04.062. PMID 15914010.
  5. ^ Elsom LF, Biggs SR, Chasseaud LF, Hawkins DR, Pulsford J, Darragh A (1985). "Metabolism of the anti-depressant lortalamine". European Journal of Drug Metabolism and Pharmacokinetics. 10 (3): 209–15. doi:10.1007/bf03189744. PMID 4085522. S2CID 2196891.
  6. ^ Mally C, Thiebault JJ (1990). "Ocular toxicity in beagle dogs with lortalamine, a non tricyclic antidepressant compound". Drug and Chemical Toxicology. 13 (4): 309–23. doi:10.3109/01480549009032289. PMID 2279460.
  7. ^ Ding YS, Lin KS, Logan J, Benveniste H, Carter P (July 2005). "Comparative evaluation of positron emission tomography radiotracers for imaging the norepinephrine transporter: (S,S) and (R,R) enantiomers of reboxetine analogs (methylreboxetine, 3-Cl-methylreboxetine and fluororeboxetine), (R)-nisoxetine, oxaprotiline and lortalamine". Journal of Neurochemistry. 94 (2): 337–51. doi:10.1111/j.1471-4159.2005.03202.x. PMID 15998285. S2CID 25110597.
  8. ^ Ding YS, Lin KS, Logan J (2006). "PET imaging of norepinephrine transporters". Current Pharmaceutical Design. 12 (30): 3831–45. doi:10.2174/138161206778559687. PMID 17073682.